: mesothelioma attorney pennsylvania

 

Pennsylvania Mesothelioma Lawyers

 

 

Dear As we collected figures institutions are benefiting from as much as we have said, just as tumor lawyers with specific expertise, training, and patients who seek medical experts who have the experience and education, focusing on this type of cancer. Pennsylvania Mesothelioma lawyers review the records of the patient and build a legal case on the basis of a thorough and comprehensive documentation of medical professionals. Although these doctors are not endorsed by this site, because they do not specialize in tumor treatment and care, evidence that this rare form of cancer requires management experts from medical professior

 

 

LawInfo Lead qualified lawyers for lawyers tumor

 

Roy W. Smith, MD

 

 

 

 

 

Professor and Chairman / Department of Surgery, Texas A & M University System Health Science Center, Scott and White Hospital, Temple, TXPhone: 254-724-2595 Dr. Smith is currently compiling a protocol involving patients pneumonectomy extrapleural and intensity modulated radiation therapy (IMRT).

 

 

 

 

 

 

David C. Rice, MD

 

 

 

 

 

Assistant Surgeon and Assistant Professor of Surgery and director of the tumor, and director of the Laparoscopic Surgery, Thoracic Surgery / University of Texas MD Anderson Cancer Center in Houston, TXPhone: (713) 794-1477

 

 

Dr. Rice is currently concluding the second phase of enrollment of the trial pneumonectomy extrapleural (European People's Party), followed by intensity modulated radiation therapy (IMRT). It is also planned for a new trial before surgery Alimta / cisplatin followed by EPP and IMR

 

 

David J. Sugarbaker, MD

 

 

 

 

 

Chief of Thoracic Surgery / Brigham and Women's Hospital in Boston, MA Chief of Surgical Services / Dana-Farber Cancer Institute, Boston, MAPhone: (617) 732-6824 Dr. Sugarbaker supports the treatment of mesothelioma pleural aggressive. It calls for the unconditional triple combination therapy; pneumonectomy extrapleural, chemotherapy and radiation

 

 

Valerie George Roche, FACS

 

 

 

 

 

Attend the chest surgeon / Memorial Sloan-Kettering Cancer Center, New York, NYPhone: (212) 639-5873 Dr. Roche is recognized among medical professionals to treat pleural mesothelioma, and has written several papers on the cortex as compared to pleural pneumonectomy extrapleu

 

 

 

Raja M. Flores, MD

 

 

 

 

 

Attend the chest surgeon / Memorial Sloan-Kettering Cancer Center, New York, NYPhone: (212) 639-2806 Dr. Flores serves as the principal investigator of a clinical trial of cisplatin and gemcitabine neoadjuvant followed by pneumonectomy extrapleural and high-dose radiation. Also participate in the trial of Alimta neoadjuvant / cisplatin, pneumonectomy extrapleural and high dose of radiation. Has also compiled a 1,000 patient database to research areas of failure, and how to improve treatment for mesothelioma.

 

 

 

Paul H.. Sugarbaker, MD, FACS, FRCS

 

 

 

 

 

Director of surgery, oncology / Washington Cancer Institute, Washington, DCPhone: (202) 877-3908 Dr. Sugarbaker is a specialist in the treatment of peritoneal mesothelioma using a combination of surgery, chemotherapy and radiation

Brian W. Loggie, MD

 

 

 

 

 

Professor of Surgery, Creighton University School of Medicine, Chief of surgical oncology and director of Cancer Center / Medical Center, Creighton University, Omaha, NEPhone: (402) 280-4100 Dr. Loggie specializes in the treatment of peritoneal mesothelioma and peritoneal carcinomatosis. Protocol, and, on an accrual basis, and includes surgical debulking in conjunction with chemotherapy intraperitoneal hot

 

Claire F. Verschraegen, MD

 

 

 

 

 

Director, Office of clinical trials and testing of the drug program / Cancer Research and Treatment Center, University of New Mexico, Albuquerque, and NMPhone: (505) 272-4551 d. Verschraegen is currently conducting front-line Alimta / gemcitabine trial for patients with peritoneal mesothelioma. It also provides the first phase of the following experiments for patients who have been treated with Alimta:

 

• phase I study of Capecitabine with Irinotecan and cisplatin in advanced patients who suffer from malignant tumors

 

 

 

 

 

• Phase I study of intravenous TZT - 1027 and Gemcitabine, given a day (1) and on 8 of the three-week advanced course in patients with solid tumors

 

 

 

 

 

• Phase I of the study in Flavoperidol Combination with Gemcitabine and Irinotecan in transition in the patients suffering from cancer

 

 

 

 

 

David B.. Mason, MD

 

 

 

 

 

Staff surgeon, Department of Thoracic and Cardiovascular / Cleveland Clinic Foundation, Cleveland, Ohio Phone: (216) 444-4053 Dr. Mason supports the aggressive multimodality treatment for malignant mesothelioma. This includes pneumonectomy extrapleural, chemotherapy and radiation with intensity modulated radiation therapy (IMRT). The Cleveland Clinic for Thoracic Oncology has a multidisciplinary team with extensive experience and clinical trials in the management of malignant mesothelioma

 

 

 

 

 

David M.. Jablons, MD

 

 

 

 

 

Assistant Professor of Surgery, the Prime Minister, General Thoracic Surgery / UCSF Mt. Zion Medical Center in San Francisco, CAPhone: (415) 885-3882 Dr. Jablons runs pleural mesothelioma with radical pleurectomy / Decortication, and is looking at other treatments

 

Larry A. Robinson, MD

 

 

 

 

 

Director, Division of Thoracic Surgery, heart and major blood vessels chest surgical oncology / H. Lee Moffitt Cancer Center and Research Institute, Tampa, FLPhone: (813) 972-8412 Dr. Robinson is a member of a multidisciplinary team in thoracic oncology H. Lee Moffitt Cancer Center where he was staying and address all stages of mesothelioma. And also participate in clinical research programs for lung cancer and mesothelioma

 

 

Robert N. Top, MD

 

 

 

 

 

Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons / New York Presbyterian Hospital, New York, NYPhone: (212) 305-4076 Dr. Robert is the top medical oncology and director of the Oncology connective tissue in the Herbert Irving Comprehensive Cancer Center and participated in several ongoing studies of multimodality patients who suffer from pleural and peritoneal mesothelioma. The Center is located at Columbia University College of Physicians and Surgeons.

 

 

Daniel Sterman, MD

Assistant Professor, Department of Medicine / University of Pennsylvania Medical Center, Philadelphia, PAPhone: (215) 614-0984 Dr. Sterman He has published several articles on treatment and clinical trials for pleural mesothelioma

Eric Vallieres, MD

 

 

 

 

 

Assistant Professor of Surgery, Department of General Thoracic Surgery / University of Washington Medical Center, Seattle, WAPhone: (206) 598-4477 Dr. Vallieres employs a multidisciplinary approach in the chest, and malignancies related to clinical trials. Dr Vallieres participated in writing an article about chemotherapy induction, extra-thyroid Pneumonectomy and vaccines to help fast neutron for Radiationtherapy gland tum

 

 

Stephen C. Yang, MD

 

 

 

 

 

Chief of Thoracic Surgery / Professor of Surgery and Oncology / Surgical Director of Lung Transplantation Program / Director, Thoracic Oncology Program / Johns Hopkins Medical Institutions in Baltimore, Maryland Phone: (410) 614-3891

 

Mark J. Krasna, MD

 

 

 

 

 

Chief of Thoracic Surgery / University of Maryland School of Medicine, and director of the Thoracic Oncology / University of Maryland Greenebaum Cancer Center, Baltimore, -6366 d. Krasna has been published widely on the role of the multidisciplinary treatment of lung cancer and esophagus. He is the principal investigator for trimodality protocol for treatment of pleural mesothelioma at the University of Maryland. It is also an investigator in the treatment of pleural mesothelioma

---

Hotmail: بريد إلكتروني قوي ومجاني ويتمتع بحماية Microsoft. احصل عليه الآن.